Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.035
Neutral
RSI(14)
50.842
Neutral
STOCH(KDJ)(9,3,3)
75.908
Neutral
ATR(14)
0.072
Low Volatility
CCI(14)
110.826
Buy
Williams %R
26.087
Buy
TRIX(12,20)
-0.308
Sell
StochRSI(14)
68.015
Sell
Fate Therapeutics Inc
FATE1.110USD
-0.010-0.89%
Market hours （ET）Quotes delayed by 15 min
128.02MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Fate Therapeutics Inc
Currency: USD Updated: 2025-12-15Key Insights
Fate Therapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 117/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.94.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current strong trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fate Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
4.944
Target Price
+362.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Fate Therapeutics Inc Highlights
StrengthsRisks
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Growing
The company is in a growing phase, with the latest annual income totaling USD 13.63M.
Overvalued
The company’s latest PE is -0.85, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 8.80M shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-15The current financial score of Fate Therapeutics Inc is 5.40, ranking 382/404 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.74M, representing a year-over-year decrease of 43.36%, while its net profit experienced a year-over-year decrease of 32.36%.
Score
Financials
5.64
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.31
Operational Efficiency
2.83
Growth Potential
4.15
Shareholder Returns
7.07
Fate Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-12-15The current valuation score of Fate Therapeutics Inc is 8.80, ranking 17/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.85, which is -45.89% below the recent high of -0.46 and -502.00% above the recent low of -5.11.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 117/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-15The current earnings forecast score of Fate Therapeutics Inc is 7.50, ranking 283/404 in the Biotechnology & Medical Research industry. The average price target for Fate Therapeutics Inc is 5.00, with a high of 8.00 and a low of 2.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
4.944
Target Price
+362.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
62
Total
5
Median
6
Average
Company name
Ratings
Analysts
Fate Therapeutics Inc
FATE
12
Apple Inc
AAPL
50
Ge Vernova Inc
GEV
34
FMC Corp
FMC
21
Tapestry Inc
TPR
21
Verisk Analytics Inc
VRSK
20
1
2
3
...
13
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-15The current price momentum score of Fate Therapeutics Inc is 5.62, ranking 322/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.20 and the support level at 1.00, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.104
Buy
MA10
1.085
Buy
MA20
1.067
Buy
MA50
1.239
Sell
MA100
1.150
Sell
MA200
1.131
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-15The current institutional shareholding score of Fate Therapeutics Inc is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 121.91%, representing a quarter-over-quarter decrease of 1.55%. The largest institutional shareholder is Catherine Wood, holding a total of 10.31M shares, representing 8.94% of shares outstanding, with 0.62% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Redmile Group, LLC
BlackRock Institutional Trust Company, N.A.
Johnson & Johnson Innovation-JJDC, Inc.
Acadian Asset Management LLC
Geode Capital Management, L.L.C.
Vestal Point Capital, LP
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-15The current risk assessment score of Fate Therapeutics Inc is 2.62, ranking 223/404 in the Biotechnology & Medical Research industry. The company's beta value is 2.21. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
2.21
VaR
+8.06%
240-Day Maximum Drawdown
+63.64%
240-Day Volatility
+106.24%
Return
Best Daily Return
60 days
+26.00%
120 days
+26.00%
5 years
+26.00%
Worst Daily Return
60 days
-14.98%
120 days
-14.98%
5 years
-61.45%
Sharpe Ratio
60 days
+0.94
120 days
+0.32
5 years
-0.51
Risk Assessment
Maximum Drawdown
240 days
+63.64%
3 years
+91.86%
5 years
+99.30%
Return-to-Drawdown Ratio
240 days
-0.49
3 years
-0.30
5 years
-0.20
Skewness
240 days
+0.75
3 years
+0.80
5 years
-0.43
Volatility
Realised Volatility
240 days
+106.24%
5 years
+102.39%
Standardised True Range
240 days
+10.39%
5 years
+135.13%
Downside Risk-Adjusted Return
120 days
+62.49%
240 days
+62.49%
Maximum Daily Upside Volatility
60 days
+81.14%
Maximum Daily Downside Volatility
60 days
+59.47%
Liquidity
Average Turnover Rate
60 days
+1.48%
120 days
+1.59%
5 years
--
Turnover Deviation
20 days
-36.65%
60 days
-26.77%
120 days
-21.71%
Peer Comparison
Biotechnology & Medical Research
Fate Therapeutics Inc
FATE
6.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Fate Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Fate Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Fate Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Fate Therapeutics Inc?
To generate the financial health score of Fate Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Fate Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Fate Therapeutics Inc.
How do we generate the company valuation score of Fate Therapeutics Inc?
To generate the company valuation score of Fate Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Fate Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Fate Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Fate Therapeutics Inc.
How do we generate the earnings forecast score of Fate Therapeutics Inc?
To calculate the earnings forecast score of Fate Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Fate Therapeutics Inc’s future.
How do we generate the price momentum score of Fate Therapeutics Inc?
When generating the price momentum score for Fate Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Fate Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Fate Therapeutics Inc.
How do we generate the institutional confidence score of Fate Therapeutics Inc?
To generate the institutional confidence score of Fate Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Fate Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Fate Therapeutics Inc.
How do we generate the risk management score of Fate Therapeutics Inc?
To assess the risk management score of Fate Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Fate Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Fate Therapeutics Inc.
